Abstract

Cell motility is a critical feature of invasive tumour cells that is governed by complex signal transduction events. Particularly, the underlying mechanisms that bridge extracellular stimuli to the molecular machinery driving motility remain partially understood. Here, we show that the scaffold protein CNK2 promotes cancer cell migration by coupling the pro-metastatic receptor tyrosine kinase AXL to downstream activation of ARF6 GTPase. Mechanistically, AXL signalling induces PI3K-dependent recruitment of CNK2 to the plasma membrane. In turn, CNK2 stimulates ARF6 by associating with cytohesin ARF GEFs and with a novel adaptor protein called SAMD12. ARF6-GTP then controls motile forces by coordinating the respective activation and inhibition of RAC1 and RHOA GTPases. Significantly, genetic ablation of CNK2 or SAMD12 reduces metastasis in a mouse xenograft model. Together, this work identifies CNK2 and its partner SAMD12 as key components of a novel pro-motility pathway in cancer cells, which could be targeted in metastasis.

Cancer cell motility is necessary for cell invasion and metastasis. Here, the authors identify CNK2 as a key mediator of cancer cell motility, linking extracellular stimuli via AXL signalling and downstream activation of ARF6 GTPase, resulting in increased metastasis in preclinical models.

Details

Title
CNK2 promotes cancer cell motility by mediating ARF6 activation downstream of AXL signalling
Author
Serwe, Guillaume 1 ; Kachaner, David 2 ; Gagnon, Jessica 1 ; Plutoni, Cédric 2 ; Lajoie, Driss 2 ; Duramé, Eloïse 1 ; Sahmi, Malha 2 ; Garrido, Damien 2   VIAFID ORCID Logo  ; Lefrançois, Martin 2 ; Arseneault, Geneviève 2 ; Saba-El-Leil, Marc K. 2 ; Meloche, Sylvain 3   VIAFID ORCID Logo  ; Emery, Gregory 4   VIAFID ORCID Logo  ; Therrien, Marc 4   VIAFID ORCID Logo 

 Université de Montréal, Institute for Research in Immunology and Cancer, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Université de Montréal, Molecular Biology Program, Faculty of Medicine, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357) 
 Université de Montréal, Institute for Research in Immunology and Cancer, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357) 
 Université de Montréal, Institute for Research in Immunology and Cancer, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Université de Montréal, Molecular Biology Program, Faculty of Medicine, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Université de Montréal, Department of Pharmacology and Physiology, Faculty of Medicine, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357) 
 Université de Montréal, Institute for Research in Immunology and Cancer, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Université de Montréal, Molecular Biology Program, Faculty of Medicine, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Université de Montréal, Department of Pathology and Cell Biology, Faculty of Medicine, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357) 
Pages
3560
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2826998013
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.